GRAIL, Inc. Common Stock Canaccord Genuity's 46th Annual Growth Conference

Yeah. Thanks for having us.

Yeah, no, thanks for the questions. Thanks for having us. Yeah, so we're really happy with the first half. We had a revenue growth of about 30% and volume growth of about 42%, over 117,000 tests now in the first half. We've been really focused on building this market in this pay reimbursement space, whether it's through digital health or self-insured employers, in addition to your brick-and-mortar physician offices. We continue to see growth, really, in the digital health and the employer channel space. We've expanded our sales force. That effort really started this quarter in Q2, and it completed by the end of it. We had everybody up and trained by the end of it, and we'll see those sales folks out in the field here shortly. Actually, they are out there now. We also released data at NHS-Galleri data at ASCO.

We've trained the sales force on that now, and they're out having really good conversations with physicians. It's pretty significant, clinically meaningful stage 4 reduction, for an intended screening test, like an I.M. said. No one's demonstrated that before. That's pretty important. I think the things really driving growth right now are traction in those channels, and then the education of those sales reps now having the ASCO data in hand.

I mean, athenahealth and Quest have been in place now for over a year.

Yeah. What we've found is once a physician is bought in and they are detecting cancers, that really removes the friction from the system.

It makes it much easier for them to order. So physicians who use that and are bought in are ordering more tests. What we're excited about is by the end of the year, we'll have Epic integrated, which will be even further friction removing for physicians.

Yeah. I mean, digital health is a really big opportunity for us, and we've seen that really through Function. These digital health platforms are built to go out and find customers who are proactive about their health, which lines up very nicely with our test. People who want to find cancer before their symptoms. As they make it available, it's very efficient for us from a sales perspective. They drive the marketing. They drive the selling and retention of the customer. But we've also learned that it's very impacted by their level of investment in the marketing and whatever products that they're pushing. So Function has been a very good partner. Our digital health channel overall volumes have grown, doubled quarter-over-quarter compared to last year, which is nice to see. But we're really just beginning that journey into the digital health channel.

We'd had a launch with Hims & Hers earlier this year. Their attention has been focused on their GLP-1 business, not so much on their labs business, so their investment hasn't really been made currently. But that's upside when that happens.